The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
COMy 2024 | The management of triple-class refractory myeloma in the absence of immunotherapies
Lisa Leypoldt, MD, University Medical Center Hamburg, Hamburg, Germany, discusses the management of triple-class refractory patients with multiple myeloma (MM) in the absence of immunotherapies. Classical therapies such as immunomodulatory drugs (IMiDs), proteasome inhibitors, and monoclonal antibodies are the first options to treat myeloma. If patients are refractory to these, agents with different mechanisms of action should be considered, such as selinexor or belantamab mafodotin. This interview took place at The 10th World Congress on Controversies in Multiple Myeloma (COMy) in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
